Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nihon Dempa Kogyo, commonly branded as NDK, is a Japanese public company that manufactures quartz crystal and other frequency-control products, including crystal units, crystal oscillators, crystal filters, synthetic quartz, SAW devices, QCM sensors, outgas analysis systems, and ultrasonic transducers. The company primarily serves electronics end markets such as automotive, smartphones and IoT devices, communications infrastructure, data centers, consumer electronics, aerospace, and industrial equipment. It also has exposure to medical and healthcare applications through products such as ultrasonic transducers and certain sensing products, but it is not a biotechnology or pharmaceutical developer. NDK operates global manufacturing, sales, and R&D sites and is listed on the Prime Market of the Tokyo Stock Exchange. For a biotech analyst, the key point is that this is a diversified electronics/components manufacturer with some medical-device-adjacent offerings rather than a life sciences therapeutics company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nihon Dempa Kogyo.